Statins, Angiotensin‐Converting Enzyme Inhibitors, and Physical Performance in Older Women

To examine associations between angiotensin‐converting enzyme (ACE) inhibitor and statin medications and baseline and mean annual change in physical performance measures and muscle strength in older women.

[1]  S. Studenski,et al.  Angiotensin‐Converting Enzyme Inhibitor and Statin Use and Incident Mobility Limitation in Community‐Dwelling Older Adults: The Health, Aging and Body Composition Study , 2011, Journal of the American Geriatrics Society.

[2]  S. Studenski,et al.  Gait speed and survival in older adults. , 2011, JAMA.

[3]  D. Sumukadas,et al.  Optimal management of sarcopenia , 2010, Clinical interventions in aging.

[4]  E. Hoffman,et al.  A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. , 2010, Preventive cardiology.

[5]  F. Lattanzio,et al.  Targeting inflammation to slow or delay functional decline: where are we? , 2010, Biogerontology.

[6]  S. Rubin,et al.  Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[7]  L. Blizzard,et al.  Statin therapy, muscle function and falls risk in community-dwelling older adults. , 2009, QJM : monthly journal of the Association of Physicians.

[8]  D. Siscovick,et al.  Test-retest reliability of the Women's Health Initiative physical activity questionnaire. , 2009, Medicine and science in sports and exercise.

[9]  A. LaCroix,et al.  Angiotensin‐Converting Enzyme Inhibitor Use and Incident Frailty in Women Aged 65 and Older: Prospective Findings from the Women's Health Initiative Observational Study , 2009, Journal of the American Geriatrics Society.

[10]  A. LaCroix,et al.  Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[11]  D. Abernethy,et al.  Physical and Cognitive Performance and Burden of Anticholinergics, Sedatives, and ACE Inhibitors in Older Women , 2008, Clinical pharmacology and therapeutics.

[12]  M. Mcmurdo,et al.  Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial , 2007, Canadian Medical Association Journal.

[13]  J. Concato,et al.  Effects of Statin Use on Muscle Strength, Cognition, and Depressive Symptoms in Older Adults , 2007, Journal of the American Geriatrics Society.

[14]  S. Studenski,et al.  Research Agenda for Frailty in Older Adults: Toward a Better Understanding of Physiology and Etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults , 2006, Journal of the American Geriatrics Society.

[15]  C. Reid,et al.  Brief Communication: Ramipril Markedly Improves Walking Ability in Patients with Peripheral Arterial Disease , 2006, Annals of Internal Medicine.

[16]  S. Studenski,et al.  Meaningful Change and Responsiveness in Common Physical Performance Measures in Older Adults , 2006, Journal of the American Geriatrics Society.

[17]  L. Ferrucci,et al.  Statin use and functional decline in patients with and without peripheral arterial disease. , 2006, Journal of the American College of Cardiology.

[18]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[19]  T. Lumley,et al.  Weight Loss, Muscle Strength, and Angiotensin‐Converting Enzyme Inhibitors in Older Adults with Congestive Heart Failure or Hypertension , 2005, Journal of the American Geriatrics Society.

[20]  S. Rubin,et al.  Inflammatory Markers and Incident Mobility Limitation in the Elderly , 2004, Journal of the American Geriatrics Society.

[21]  Mark A. Creager,et al.  Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease , 2003, Circulation.

[22]  S. Mondillo,et al.  Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. , 2003, The American journal of medicine.

[23]  L. Sharma,et al.  Statin Use and Leg Functioning in Patients With and Without Lower-Extremity Peripheral Arterial Disease , 2003, Circulation.

[24]  Suzanne G. Leveille,et al.  Change in Muscle Strength Explains Accelerated Decline of Physical Function in Older Women With High Interleukin‐6 Serum Levels , 2002, Journal of the American Geriatrics Society.

[25]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[26]  L. Fried,et al.  Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. , 2002, Archives of internal medicine.

[27]  M. Mcmurdo,et al.  Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial , 2002, Heart.

[28]  P. Lapuerta,et al.  Change in physical performance over time in older women: the Women's Health and Aging Study. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[29]  J. Williamson,et al.  Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study , 2002, The Lancet.

[30]  Robert D. Langer,et al.  Short version of the CES-D (Burnam screen) for depression in reference to the structured psychiatric interview , 2001, Psychiatry Research.

[31]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[32]  L. Ferrucci,et al.  Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[33]  Suzanne G. Leveille,et al.  Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[34]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[35]  Luigi Ferrucci,et al.  Serum IL‐6 Level and the Development of Disability in Older Persons , 1999, Journal of the American Geriatrics Society.

[36]  Stella M. Yu.  Healthy People 2010 , 1998, Maternal and Child Health Journal.

[37]  L. Ferrucci,et al.  A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. , 1994, Journal of gerontology.

[38]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[39]  K. Wells,et al.  Development of a Brief Screening Instrument for Detecting Depressive Disorders , 1988, Medical care.

[40]  M. Cesari,et al.  ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. , 2010, Journal of the American Medical Directors Association.

[41]  Richard W. Bohannon.  Hand‐Grip Dynamometry Predicts Future Outcomes in Aging Adults , 2008, Journal of geriatric physical therapy.

[42]  B. Golomb,et al.  Statin Adverse Effects , 2008, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[43]  Matthew A Silva,et al.  Statin-related adverse events: a meta-analysis. , 2006, Clinical therapeutics.

[44]  Ack,et al.  LOWER-EXTREMITY FUNCTION IN PERSONS OVER THE AGE OF 70 YEARS AS A PREDICTOR OF SUBSEQUENT DISABILITY , 2001 .

[45]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[46]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .